1. Home
  2. WLFC vs VRDN Comparison

WLFC vs VRDN Comparison

Compare WLFC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Willis Lease Finance Corporation

WLFC

Willis Lease Finance Corporation

HOLD

Current Price

$135.43

Market Cap

1.0B

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$32.44

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WLFC
VRDN
Founded
1985
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
2.7B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
WLFC
VRDN
Price
$135.43
$32.44
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$39.73
AVG Volume (30 Days)
45.7K
1.6M
Earning Date
11-04-2025
11-05-2025
Dividend Yield
1.18%
N/A
EPS Growth
17.99
N/A
EPS
16.70
N/A
Revenue
$674,381,000.00
$70,789,000.00
Revenue This Year
$16.17
$26,477.48
Revenue Next Year
$1.26
$6.23
P/E Ratio
$8.14
N/A
Revenue Growth
29.58
23340.07
52 Week Low
$114.01
$9.90
52 Week High
$229.67
$33.34

Technical Indicators

Market Signals
Indicator
WLFC
VRDN
Relative Strength Index (RSI) 60.37 65.20
Support Level $126.56 $31.11
Resistance Level $141.71 $33.29
Average True Range (ATR) 5.31 1.23
MACD 1.89 -0.17
Stochastic Oscillator 74.24 69.57

Price Performance

Historical Comparison
WLFC
VRDN

About WLFC Willis Lease Finance Corporation

Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Share on Social Networks: